<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rifaximin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rifaximin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Rifaximin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11425" href="/d/html/11425.html" rel="external">see "Rifaximin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="94528" href="/d/html/94528.html" rel="external">see "Rifaximin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F218514"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Xifaxan</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868158"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Zaxine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F218531"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Rifamycin</li></ul></div>
<div class="block doa drugH1Div" id="F218516"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>The 200 mg tablet may not be available in some international markets; consult local product labeling for availability.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6bda31d3-8c70-4c8c-9bda-588b02753ab9">
<i>Clostridioides difficile</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Clostridioides difficile</i> infection (second or subsequent recurrence) (alternative regimen) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Rifaximin resistance may be a concern; some experts avoid in patients who have previously received rifamycins, and others do not routinely recommend this regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176','lexi-content-ref-Kelly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176','lexi-content-ref-Kelly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 400 mg 3 times daily for 20 days; administer after a 10-day course of oral vancomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21948965','lexi-content-ref-34164674','lexi-content-ref-17304459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21948965','lexi-content-ref-34164674','lexi-content-ref-17304459'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="642e4653-1ebe-404d-bff9-bf03c8990b70">Hepatic encephalopathy, treatment or prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic encephalopathy, treatment (off-label use) or prevention:</b>
<b>Note:</b> Use as an adjunct or alternative to nonabsorbable disaccharides (eg, lactulose) in patients intolerant of or with insufficient response to disaccharides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25042402','lexi-content-ref-Ferenci.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25042402','lexi-content-ref-Ferenci.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 550 mg twice daily <b>or</b> 400 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25042402','lexi-content-ref-Ferenci.1','lexi-content-ref-23092866','lexi-content-ref-7555036']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25042402','lexi-content-ref-Ferenci.1','lexi-content-ref-23092866','lexi-content-ref-7555036'])">Ref</a></span>). When used for treatment of an acute episode, continue therapy for at least 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ferenci.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ferenci.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc5f3892-5671-420b-8046-d0240a71800f">Irritable bowel syndrome, moderate to severe, without constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritable bowel syndrome, moderate to severe, without constipation (alternative agent):</b>
<b>Note:</b> Reserve for patients, particularly those with bloating, who have failed other therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27528177','lexi-content-ref-21559740','lexi-content-ref-Wald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27528177','lexi-content-ref-21559740','lexi-content-ref-Wald.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 550 mg 3 times daily for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27528177','lexi-content-ref-21559740','lexi-content-ref-Wald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27528177','lexi-content-ref-21559740','lexi-content-ref-Wald.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1f50b060-541c-4587-a829-2e09ca7dcc12">Pouchitis, acute refractory disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pouchitis (post ileal pouch-anal anastomosis), acute refractory disease (off-label use):</b>
<b>Oral:</b> 550 mg to 1 g every 12 hours in combination with ciprofloxacin for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15720360','lexi-content-ref-10383499','lexi-content-ref-Shen.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15720360','lexi-content-ref-10383499','lexi-content-ref-Shen.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5b976b88-c8e8-47cc-a9b2-253040d56ea0">Small intestinal bacterial overgrowth</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small intestinal bacterial overgrowth (off-label use): Oral:</b> 550 mg 3 times daily for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32023228','lexi-content-ref-Pimentel.2019','lexi-content-ref-17373916']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32023228','lexi-content-ref-Pimentel.2019','lexi-content-ref-17373916'])">Ref</a></span>). For patients with methane-predominant bacterial overgrowth, some experts use rifaximin as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pimentel.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pimentel.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2379526-dc80-4140-a84e-a006a755f3c0">Travelers’ diarrhea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Travelers’ diarrhea:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis (off-label use): </i>
<b>Note: </b>Routine prophylaxis is not recommended. Reserve for select short-term travelers (eg, &lt;2 weeks) at high risk of complications from diarrheal illness. Effectiveness for travelers to South and Southeast Asia may be reduced (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28521004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28521004'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 200 mg 1 to 3 times daily for the duration of travel; optimal dose and duration not well established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15897530','lexi-content-ref-23379704','lexi-content-ref-LaRocque.1','lexi-content-ref-25562268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15897530','lexi-content-ref-23379704','lexi-content-ref-LaRocque.1','lexi-content-ref-25562268'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, moderate to severe (alternative agent):</i>
<b>Note: </b>Avoid in patients with fever or bloody diarrhea. Most cases are self-limited and may not warrant antimicrobial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-LaRocque.1','lexi-content-ref-28521004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-LaRocque.1','lexi-content-ref-28521004'])">Ref</a></span>). Some experts reserve antimicrobial therapy for certain high-risk travelers (eg, those with an immunocompromising condition) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-LaRocque.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-LaRocque.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 200 mg 3 times daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28521004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28521004'])">Ref</a></span>); consider alternative therapy if symptoms persist or worsen after 24 to 48 hours of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991954"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed: No supplemental dose or dosage adjustment necessary (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed: No dosage adjustment necessary (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989250"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. Use with caution in severe impairment (Child-Pugh class C); however, systemic absorption is limited and pharmacokinetic parameters are highly variable.</p></div>
<div class="block doe drugH1Div" id="F218517"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F218524"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="94528" href="/d/html/94528.html" rel="external">see "Rifaximin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> The 200 mg tablet may not be available in some international markets; consult local product labeling for availability.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6bda31d3-8c70-4c8c-9bda-588b02753ab9">
<i>Clostridioides difficile</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Clostridioides difficile</i> infection (second or subsequent recurrence):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;12 years: Very limited data available: Oral: 15 to 30 mg/kg/day in divided doses 3 times daily for 20 days; usual adult dose: 400 mg/dose; administer after a 10-day course of oral vancomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-29084080','lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-29084080','lexi-content-ref-29462280'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 400 mg 3 times daily for 20 days; administer after a 10-day course of oral vancomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21948965','lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21948965','lexi-content-ref-29462280'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9117d6e1-33df-4646-bf4f-7e3751815245">Inflammatory bowel disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inflammatory bowel disease (IBD) (Crohn disease, ulcerative colitis):</b> Limited data available: Children ≥8 years and Adolescents: Oral: 10 to 30 mg/kg/day in divided doses; maximum daily dose: 1,200 mg/<b>day</b>. Dosing based on a retrospective experience of 23 pediatric patients (age range: 8 to 21 years) with IBD flare (Crohn disease: n=12; ulcerative colitis: n=11); patients received rifaximin 400 to 1,200 mg/day (10 to 30 mg/kg/day); improvements in diarrhea and abdominal pain were reported within the first 4 weeks of therapy for the majority of patients (~74%), and within a week in some cases; higher total daily doses (1,200 mg/day vs 400 mg/day) were associated with better symptom control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19668011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19668011'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5b976b88-c8e8-47cc-a9b2-253040d56ea0">Small intestinal bacterial overgrowth</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small intestinal bacterial overgrowth (SIBO) (eg, associated with irritable bowel syndrome [IBS], short bowel syndrome, chronic abdominal pain):</b> Limited data available; efficacy results variable.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 3 to &lt;8 years: Oral: 200 mg 3 times daily for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29280097','lexi-content-ref-23740443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29280097','lexi-content-ref-23740443'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥8 years and Adolescents: Oral: 200 to 550 mg 3 times daily for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29280097','lexi-content-ref-21240023','lexi-content-ref-23740443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29280097','lexi-content-ref-21240023','lexi-content-ref-23740443'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on expert recommendations and a prospective study of 50 pediatric patients with SIBO and IBS (age range: 3 to 15 years); results showed 7 days of therapy resulted in improved symptoms and a reduction in bacterial overgrowth based on lactulose breath test (LBT) results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23740443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23740443'])">Ref</a></span>); however, a double-blind placebo-controlled trial in pediatric patients (n=75 including 49 who received rifaximin; age range: 8 to 18 years) with SIBO and chronic abdominal pain showed very low efficacy in normalizing LBT (20% response rate) and treating SIBO compared to placebo at a higher dose of 550 mg 3 times daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21240023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21240023'])">Ref</a></span>). Based on adult experience, some experts use rifaximin as part of an appropriate combination regimen in patients with methane-predominant bacterial overgrowth (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pimentel.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pimentel.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8371a59a-1dc4-47ca-aaef-c1e699b5bc49">Travelers' diarrhea, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Travelers' diarrhea, treatment:</b>
<b>Note:</b> Avoid use in diarrhea with fever or blood in the stool or diarrhea caused by pathogens other than <i>E. coli</i>; consider alternative therapy if symptoms persist or worsen after 24 to 48 hours of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 3 to 11 years: Limited data available: Oral: 100 mg 4 times daily for up to 5 days has been used in 38 children (age range: 3 to 8 years) to treat infectious diarrhea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10546408','lexi-content-ref-9524792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10546408','lexi-content-ref-9524792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 200 mg 3 times daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159861"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51159862"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years and Adolescents: Oral: No dosage adjustment necessary. Use with caution in patients with severe impairment as systemic exposure is increased and pharmacokinetic parameters are highly variable.</p></div>
<div class="block arsc drugH1Div" id="F58073895"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Infection due to inappropriate use/unexpected failure of therapy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Although rifaximin is used to treat the pathogens associated with travelers' diarrhea, <i>Clostridioides difficile</i>-associated infection or to reduce bacterial overgrowth in the setting of various disease states, it is ineffective against invasive pathogens (eg, <i>Campylobacter jejuni</i>, <i>Shigella </i>spp, and <i>Salmonella</i> spp) that cause infectious diarrhea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26618921','lexi-content-ref-21765867','lexi-content-ref-29145631','lexi-content-ref-16760520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26618921','lexi-content-ref-21765867','lexi-content-ref-29145631','lexi-content-ref-16760520'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; failure of therapy. Rifaximin is a nonabsorbable antibiotic, and pathogens that invade the tissues will not have contact with an antimicrobial agent that does not penetrate the tissues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16760520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16760520'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; inadequate improvement in diarrhea symptoms within 3 days of treatment, specifically in the setting of tissue invasive bacterial species (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16760520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16760520'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Fever associated with diarrhea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19881343','lexi-content-ref-16258326','lexi-content-ref-16760520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19881343','lexi-content-ref-16258326','lexi-content-ref-16760520'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Blood in stool (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19881343','lexi-content-ref-16258326','lexi-content-ref-16760520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19881343','lexi-content-ref-16258326','lexi-content-ref-16760520'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Tissue invasive bacterial species (<i>Campylobacter jejuni</i>, <i>Shigella </i>spp, and <i>Salmonella</i> spp) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16760520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16760520'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Increased risk of resistant infections</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Rifaximin-associated superinfections, including <i>Clostridioides difficile-</i>associated and <i>Candida spp </i>infections, may occur with the use of nonabsorbable antibiotics in certain at-risk patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20335583','lexi-content-ref-23340064','lexi-content-ref-34180023','lexi-content-ref-22155172','lexi-content-ref-23507769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20335583','lexi-content-ref-23340064','lexi-content-ref-34180023','lexi-content-ref-22155172','lexi-content-ref-23507769'])">Ref</a></span>). <b>
<i>Clostridioides difficile</i> colitis </b>has been reported in patients on rifaximin therapy for Crohn disease (non-cirrhotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22155172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22155172'])">Ref</a></span>) or for hepatic encephalopathy (cirrhotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20335583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20335583'])">Ref</a></span>). Although the incidence is low and similar studies have shown no increased risk of <i>C. difficile</i> infections with rifaximin use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23751850','lexi-content-ref-23314671','lexi-content-ref-21208106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23751850','lexi-content-ref-23314671','lexi-content-ref-21208106'])">Ref</a></span>), this has raised concern for potential risk of development of antimicrobial resistance with prolonged rifaximin use or repeated courses of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23340064','lexi-content-ref-23507769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23340064','lexi-content-ref-23507769'])">Ref</a></span>). In another study in recipients of allogeneic hematopoietic stem cell transplantation, rifaximin prophylaxis for acute graft-versus-host disease post-transplant was linked to an increased risk of micafungin‑resistant <i>Candida</i> spp infections, including invasive candidiasis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34180023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34180023'])">Ref</a></span>). Rifaximin use appears not to be a risk factor and may be protective against infections when used preoperatively in liver transplant recipients and in patients with cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31180922','lexi-content-ref-32360775','lexi-content-ref-24493238','lexi-content-ref-23314671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31180922','lexi-content-ref-32360775','lexi-content-ref-24493238','lexi-content-ref-23314671'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose- and time-related; related to cumulative exposure and impact on intestinal microbiota diversity leading to selection of opportunistic (eg, <i>Candida</i>), more virulent, or resistant pathogens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23751850','lexi-content-ref-23340064','lexi-content-ref-34180023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23751850','lexi-content-ref-23340064','lexi-content-ref-34180023'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy, prolonged (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20335583','lexi-content-ref-23340064','lexi-content-ref-22155172','lexi-content-ref-22966484','lexi-content-ref-23507769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20335583','lexi-content-ref-23340064','lexi-content-ref-22155172','lexi-content-ref-22966484','lexi-content-ref-23507769'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent or recent systemic antibiotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20335583','lexi-content-ref-23340064']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20335583','lexi-content-ref-23340064'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent or recent hospitalization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20335583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20335583'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Advanced age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20335583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20335583'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34180023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34180023'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F218487"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency of adverse events generally higher following treatment for hepatic encephalopathy (HE). Percentages are presented for HE in adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (14%; patients with irritable bowel syndrome with diarrhea: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (13%), fatigue (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatological: Pruritus (9%), skin rash (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (9%; upper abdominal pain: 6%), <i>Clostridioides difficile</i> colitis (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (7%), headache (patients with travelers' diarrhea: 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (6%), increased creatine phosphokinase in blood specimen (&lt;5%), muscle spasm (9%), myalgia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (6%), nasopharyngitis (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all indications):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome (Fritz 2014), toxic epidermal necrolysis (Fritz 2014; Patel 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile-</i>associated diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (Hynicka 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction (immediate and delayed) (Moya 2021)</p></div>
<div class="block coi drugH1Div" id="F218501"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to rifaximin, other rifamycin antibiotics, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F218485"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Efficacy for prevention of encephalopathy has not been established in patients with a Model for End-Stage Liver Disease (MELD) score &gt;25; use caution in patients with severe hepatic impairment (Child-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for treatment of systemic infections; &lt;1% is absorbed orally.</p></div>
<div class="block foc drugH1Div" id="F218495"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xifaxan: 200 mg [contains edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xifaxan: 550 mg</p></div>
<div class="block geq drugH1Div" id="F218483"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F218502"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Xifaxan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $12.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">550 mg (per each): $65.34</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868159"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 550 mg</p></div>
<div class="block adm drugH1Div" id="F218498"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food.</p></div>
<div class="block admp drugH1Div" id="F52613821"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food.</p></div>
<div class="block use drugH1Div" id="F218497"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic encephalopathy, prevention:</b> Reduction in the risk of hepatic encephalopathy recurrence in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritable bowel syndrome without constipation:</b> Treatment of moderate to severe irritable bowel syndrome without constipation in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Travelers' diarrhea:</b> Treatment of travelers' diarrhea caused by noninvasive strains of <i>Escherichia coli</i> in adults and pediatric patients ≥12 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Rifaximin should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea caused by pathogens other than <i>E. coli</i>.</p></div>
<div class="block off-label drugH1Div" id="F25725118"><span class="drugH1">Use: Off-Label: Adult</span><p>Clostridioides difficile infection (second or subsequent recurrence) (alternative regimen); Hepatic encephalopathy, treatment; Pouchitis (post ileal pouch-anal anastomosis), acute refractory disease; Small intestinal bacterial overgrowth; Travelers’ diarrhea, prophylaxis</p></div>
<div class="block mst drugH1Div" id="F803022"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">RifAXIMin may be confused with fidaxomicin, rifAMPin.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F218525"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), OATP1A2/SLCO1A2, OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> OATP1A2/SLCO1A2</p></div>
<div class="block dri drugH1Div" id="F218489"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of RifAXIMin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: RifAXIMin may diminish the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F218503"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in some animal reproduction studies. Due to the limited oral absorption of rifaximin in patients with normal hepatic function, exposure to the fetus is expected to be low. </p></div>
<div class="block brc drugH1Div" id="F218504"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if rifaximin is excreted in human milk. According to the manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Because of the limited oral absorption of rifaximin in patients with normal hepatic function, exposure to the nursing infant is expected to be low. </p></div>
<div class="block mop drugH1Div" id="F218493"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hypersensitivity reactions, temperature, blood in stool, change in symptoms; serum ammonia (as clinically indicated) (AASLD [Vilstrup 2014]).</p></div>
<div class="block pha drugH1Div" id="F218484"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Rifaximin inhibits bacterial RNA synthesis by binding to bacterial DNA-dependent RNA polymerase.</p></div>
<div class="block phk drugH1Div" id="F218500"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Travelers' diarrhea: Low</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic encephalopathy: Increased absorption in patients with Child-Pugh class C compared with patients with Child-Pugh class A</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Healthy subjects: 67.5%; Hepatic impairment: 62%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive, mainly by CYP3A</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Healthy subjects: 5.6 hours; IBS without constipation: 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Healthy subjects and patients with IBS without constipation: ~1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (96.6%; primarily as unchanged drug); urine (0.32%)</p></div>
<div class="block phksp drugH1Div" id="F51220904"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The mean AUC in patients with hepatic impairment of Child-Pugh class A, B, and C was 10-, 14-, and 21-fold higher, respectively, compared with that of healthy subjects.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539924"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Normix | Xifaxan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Normix | Rociamin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Colidimin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Xifaxan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aximin | Efaxim | Faxan | Hepatab | Hepaximin | Ibida | Rifabac | Rifacol | Rifagut | Rifamax | Rifaxin | Xifamin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Targaxan | Tixteller</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Normix</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Normix</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Xifaxan</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Xifaxan</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Normix</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">BANG YI | Fu te | Ji li qing | Jin xi li | Lai li qing | Lormyx | Mai e ke si | Ou ke shuang</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Farinil | Flonorm | Rafixmin | Rifabac | Rifadexa | Rifamed | Rifaxigal | Rifaximina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Normix</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Rifax aw | Rifaxan aw | Tixteller | Xifaxan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Farinil</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Rifanorm | Rixim</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Colidur | Normix | Rifacol</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Biofaximin | Dufaximin | Fatroxim | Gastrobiotic | Idibact | Normix | Rifaxerose | Rolaximine | Traviguard | Trencedia</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Spiraxin | Tixteller | Zaxine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Targaxan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Normix | Targaxan | Tixtar</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Targaxan | Xifaxanta</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Refero</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Normix | Xifaxan</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Normix | Targaxan | Xifaxanta</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ciboz | Dirifa | Dufaximin | Gifaxin | Gudrif | Ibifix | Rafle | Rcifax | Rfx | Rifabet | Rifabiz | Rifaclean | Rifacus | Rifadac | Rifadox | Rifadriv | Rifafix | Rifafrnd | Rifago | Rifagut | Rifajio | Rifakem | Rifamark | Rifaset | Rifastop | Rifaxigress | Rifaximax | Rifeasy | Rifgem | Rifguard | Rifigon | Rifnim | Rixmin | Rucam | Sibocure | Sibofix | Torfix | Travifix | Xifarix | Zenrif | Zimigut</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Larifax | Normix | Rifacol | Rifaximin abc | Rifaximina | Rifaximina Alter | Rifaximina big | Rifaximina Doc Generici | Rifaximina EG | Rifaximina Germed | Rifaximina Mylan | Rifaximina pensa | Rifaximina ranbaxy | Rifaximina Sandoz | Sanecol | Tixtar | Tixteller</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Xifaxan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Rifxima</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Rifaxa</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Normix</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Xifaxan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Colidur | Larifax</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Normix | Rifagut | Xifasan | Xifaxan | Xifaxan 2care4 | Xifaxan eurim</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Targaxan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Normix | Spiraxin | Xifaxan</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Normix</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Arfla | Flonorm | Itenud | Redactiv</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Faxicad</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Rifaximine medcor | Xifaxan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Normix | Xifaxan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Xifaxan</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Normix</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Normix</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Diraxim | Ecofix | Faxamin | Faxim | Faximed | Fixagut | Foxamine | Helifax | Hidrofax | Hitra | Ifaxim | Nimixa | Nixaf | Nyxia | Onlitin | Orifax | Pekny | Rafazin | Rcifax | Rfx | Rifabar | Rifagut | Rifalis | Rifaxa | Rifaxol | Rifix | Rifixa | Rifixawel | Rifmed | Rifs | Rimixa | Rixabac | Rixago | Rixawel | Rixawin | Riximid | Rixmin | Rufexa | Xifaxa | Ximin | Zanopine | Zerifax</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Tixteller | Xifaxan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Xifaxan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Refero | Xifaxan</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alfa normix | Alfaxim</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Xifaxan</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Xifaxan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Xifaxan</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Xifaxan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Normix</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Diarix | Normix</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Colidur | Hepazec | Normix | Refidex</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alfa normix | Xifaxan</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Farinil | Rifadom | Rifaxol | Rixalan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Normix | Rifamix</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Xifaxan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-15720360">
<a name="15720360"></a>Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. <i>Colorectal Dis</i>. 2005;7(2):182-186. doi:10.1111/j.1463-1318.2004.00746.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/15720360/pubmed" id="15720360" target="_blank">15720360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31180922">
<a name="31180922"></a>Bajaj JS, OʼLeary JG, Tandon P, et al. Nosocomial infections are frequent and negatively impact outcomes in hospitalized patients with cirrhosis. <i>Am J Gastroenterol</i>. 2019;114(7):1091-1100. doi:10.14309/ajg.0000000000000280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/31180922/pubmed" id="31180922" target="_blank">31180922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32360775">
<a name="32360775"></a>Bartoletti M, Rinaldi M, Pasquini Z, et al. Risk factors for candidaemia in hospitalized patients with liver cirrhosis: a multicentre case-control-control study. <i>Clin Microbiol Infect</i>. 2021;27(2):276-282. doi:10.1016/j.cmi.2020.04.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/32360775/pubmed" id="32360775" target="_blank">32360775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20335583">
<a name="20335583"></a>Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. <i>N Engl J Med</i>. 2010;362(12):1071-1081. doi:10.1056/NEJMoa0907893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/20335583/pubmed" id="20335583" target="_blank">20335583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10546408">
<a name="10546408"></a>Beseghi U, De’Angelis GL. Comparison of two non-absorbable antibiotics for treatment of bacterial enteritis in children. <i>Eur Rev Med Pharmacol Sci</i>. 1998;2(3-4):131-136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/10546408/pubmed" id="10546408" target="_blank">10546408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25319626">
<a name="25319626"></a>Boltin D, Perets TT, Shporn E, et al. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. <i>Ann Clin Microbiol Antimicrob</i>. 2014;13:49. doi: 10.1186/s12941-014-0049-x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/25319626/pubmed" id="25319626" target="_blank">25319626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS and Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23751850">
<a name="23751850"></a>Calanni F, Renzulli C, Fogli MV, Barbanti M. Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance? <i>J Clin Gastroenterol</i>. 2013;47(9):814. doi:10.1097/MCG.0b013e3182951b6c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/23751850/pubmed" id="23751850" target="_blank">23751850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29280097">
<a name="29280097"></a>Chandra R, Kesavan A. Current treatment paradigms in pediatric short bowel syndrome. <i>Clin J Gastroenterol</i>. 2018;11(2):103-112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/29280097/pubmed" id="29280097" target="_blank">29280097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21240023">
<a name="21240023"></a>Collins BS, Lin HC. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. <i>J Pediatr Gastroenterol Nutr</i>. 2011;52:382-386.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/21240023/pubmed" id="21240023" target="_blank">21240023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26618921">
<a name="26618921"></a>DuPont HL. Review article: the antimicrobial effects of rifaximin on the gut microbiota. <i>Aliment Pharmacol Ther</i>. 2016;43 Suppl 1:3-10. doi:10.1111/apt.13434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/26618921/pubmed" id="26618921" target="_blank">26618921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15897530">
<a name="15897530"></a>DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. <i>Ann Intern Med</i>. 2005;142(10):805-812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/15897530/pubmed" id="15897530" target="_blank">15897530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24493238">
<a name="24493238"></a>Esfeh JM, Hanouneh IA, Koval CE, et al. Impact of pretransplant rifaximin therapy on early post-liver transplant infections. <i>Liver Transpl</i>. 2014;20(5):544-551. doi:10.1002/lt.23845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/24493238/pubmed" id="24493238" target="_blank">24493238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23340064">
<a name="23340064"></a>Farrell DJ. Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance? <i>J Clin Gastroenterol</i>. 2013;47(3):205-211. doi:10.1097/MCG.0b013e31827559a3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/23340064/pubmed" id="23340064" target="_blank">23340064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ferenci.1">
<a name="Ferenci.1"></a>Ferenci P. Hepatic encephalopathy in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25091148">
<a name="25091148"></a>Ford AC, Moayyedi P, Lacy BE, et al. American college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. <i>Am J Gastroenterol</i>. 2014;109 (suppl 1):S2-S26. doi: 10.1038/ajg.2014.187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/25091148/pubmed" id="25091148" target="_blank">25091148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9524792">
<a name="9524792"></a>Frisari L, Viggiano V, Pelagalli M. An open, controlled study of two non-absorbable antibiotics for the oral treatment of paediatric infectious diarrhea. <i>Current Medical Research and Opinion</i>. 1997;14(1):39-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/9524792/pubmed" id="9524792" target="_blank">9524792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26157902">
<a name="26157902"></a>Fritz CD, Adebajo C, Aronsohn A, Jensen DM. A new-onset rash in the setting of rifaximin treatment for hepatic encephalopathy. <i>ACG Case Rep J</i>. 2014;2(1):42-44. doi:10.14309/crj.2014.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/26157902/pubmed" id="26157902" target="_blank">26157902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21948965">
<a name="21948965"></a>Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. <i>J Antimicrob Chemother</i>. 2011;66(12):2850-2855. doi: 10.1093/jac/dkr377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/21948965/pubmed" id="21948965" target="_blank">21948965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084080">
<a name="29084080"></a>Gawronska A, Banasiuk M, Lachowicz D, Pituch H, Albrecht P, Banaszkiewicz A. Metronidazole or rifaximin for treatment of Clostridium difficile in pediatric patients with inflammatory bowel disease: a randomized clinical trial. <i>Inflamm Bowel Dis</i>. 2017;23(12):2209-2214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/29084080/pubmed" id="29084080" target="_blank">29084080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10383499">
<a name="10383499"></a>Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. <i>Aliment Pharmacol Ther</i>. 1999;13(6):713-718. doi:10.1046/j.1365-2036.1999.00553.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/10383499/pubmed" id="10383499" target="_blank">10383499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21765867">
<a name="21765867"></a>Hong KS, Kim JS. Rifaximin for the treatment of acute infectious diarrhea. <i>Therap Adv Gastroenterol</i>. 2011;4(4):227-235. doi:10.1177/1756283X11398734<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/21765867/pubmed" id="21765867" target="_blank">21765867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23379704">
<a name="23379704"></a>Hu Y, Ren J, Zhan M, Li W, Dai H. Efficacy of rifaximin in prevention of travelers' diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials. <i>J Travel Med</i>. 2012;19(6):352-356. doi: 10.1111/j.1708-8305.2012.00650.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/23379704/pubmed" id="23379704" target="_blank">23379704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22441789">
<a name="22441789"></a>Hynicka LM, Silva KN. Probable rifaximin-induced neutropenia. <i>Am J Health Syst Pharm</i>. 2012;69(7):583-586. doi:10.2146/ajhp110164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/22441789/pubmed" id="22441789" target="_blank">22441789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34164674">
<a name="34164674"></a>Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of <i>Clostridioides difficile</i> infection in adults. <i>Clin Infect Dis</i>. 2021;73(5):e1029-e1044. doi:10.1093/cid/ciab549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/34164674/pubmed" id="34164674" target="_blank">34164674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17304459">
<a name="17304459"></a>Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. <i>Clin Infect Dis.</i> 2007;44(6):846-848.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/17304459/pubmed" id="17304459" target="_blank">17304459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kelly.1">
<a name="Kelly.1"></a>Kelly CP, Lamont JT, Bakken JS. Clostridioides (formerly Clostridium) difficile in adults: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 3, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34003176">
<a name="34003176"></a>Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. <i>Am J Gastroenterol</i>. 2021b;116(6):1124-1147. doi:10.14309/ajg.0000000000001278<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/34003176/pubmed" id="34003176" target="_blank">34003176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19881343">
<a name="19881343"></a>Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. <i>Curr Opin Gastroenterol</i>. 2010;26(1):17-25. doi:10.1097/MOG.0b013e328333dc8d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/19881343/pubmed" id="19881343" target="_blank">19881343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LaRocque.1">
<a name="LaRocque.1"></a>LaRocque R, Harris JB. Travelers' diarrhea: Epidemiology, microbiology, clinical manifestations, and diagnosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27528177">
<a name="27528177"></a>Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. <i>Gastroenterology</i>. 2016;151(6):1113-1121. doi: 10.1053/j.gastro.2016.08.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/27528177/pubmed" id="27528177" target="_blank">27528177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34180023">
<a name="34180023"></a>Marzuttini F, Mancusi A, Bonato S, et al. Rifaximin use favoured micafungin-resistant <i>Candida</i> spp. infections in recipients of allogeneic hematopoietic cell transplantation. <i>Ann Hematol</i>. 2021;100(9):2375-2380. doi:10.1007/s00277-021-04569-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/34180023/pubmed" id="34180023" target="_blank">34180023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12480560">
<a name="12480560"></a>Mas A, Rodés J, Sunyer L, et al; Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. <i>J Hepatol.</i> 2003;38(1):51-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/12480560/pubmed" id="12480560" target="_blank">12480560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi: 10.1093/cid/cix1085.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23092866">
<a name="23092866"></a>Mohammad RA, Regal RE, Alaniz C. Combination therapy for the treatment and prevention of hepatic encephalopathy. <i>Ann Pharmacother</i>. 2012;46(11):1559-1563. doi: 10.1345/aph.1R146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/23092866/pubmed" id="23092866" target="_blank">23092866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33349614">
<a name="33349614"></a>Moya B, García-Moguel I, Mielgo R, Herráez L, Crespo JF. Nonimmediate hypersensitivity reaction to rifaximin confirmed with a drug challenge test. <i>J Investig Allergol Clin Immunol</i>. 2021;31(5):453-454. doi:10.18176/jiaci.0660<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/33349614/pubmed" id="33349614" target="_blank">33349614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19668011">
<a name="19668011"></a>Muniyappa P, Gulati R, Mohr F, Hupertz V. Use and safety of rifaximin in children with inflammatory bowel disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i>. 2009;49:400-404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/19668011/pubmed" id="19668011" target="_blank">19668011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23314671">
<a name="23314671"></a>Neff GW, Jones M, Jonas M, et al. Lack of <i>Clostridium difficile</i> infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis. <i>J Clin Gastroenterol</i>. 2013;47(2):188-192. doi:10.1097/MCG.0b013e318276be13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/23314671/pubmed" id="23314671" target="_blank">23314671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16258326">
<a name="16258326"></a>Okhuysen PC. Current concepts in travelers' diarrhea: epidemiology, antimicrobial resistance and treatment. <i>Curr Opin Infect Dis</i>. 2005;18(6):522-526. doi:10.1097/01.qco.0000185987.02878.6e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/16258326/pubmed" id="16258326" target="_blank">16258326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23640348">
<a name="23640348"></a>Patel AS, Supan EM, Ali SN. Toxic epidermal necrolysis associated with rifaximin. <i>Am J Health Syst Phar</i>m. 2013;70(10):874-876. doi:10.2146/ajhp120137<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/23640348/pubmed" id="23640348" target="_blank">23640348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21208106">
<a name="21208106"></a>Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. <i>N Engl J Med</i>. 2011a;364(1):22-32. doi:10.1056/NEJMoa1004409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/21208106/pubmed" id="21208106" target="_blank">21208106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21559740">
<a name="21559740"></a>Pimentel M, Morales W, Chua K, et al. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. <i>Dig Dis Sci</i>. 2011;56(7):2067-2072. doi: 10.1007/s10620-011-1728-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/21559740/pubmed" id="21559740" target="_blank">21559740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32023228">
<a name="32023228"></a>Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. <i>Am J Gastroenterol</i>. 2020;115(2):165-178. doi:10.14309/ajg.0000000000000501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/32023228/pubmed" id="32023228" target="_blank">32023228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22155172">
<a name="22155172"></a>Prantera C, Lochs H, Grimaldi M, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. <i>Gastroenterology</i>. 2012;142(3):473-481.e4. doi:10.1053/j.gastro.2011.11.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/22155172/pubmed" id="22155172" target="_blank">22155172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7555036">
<a name="7555036"></a>Puxeddu A, Quartini M, Massimetti A, Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy. <i>Curr Med Res Opin</i>. 1995;13(5):274-281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/7555036/pubmed" id="7555036" target="_blank">7555036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28521004">
<a name="28521004"></a>Riddle MS, Connor BA, Beeching NJ, et al. Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report. <i>J Travel Med</i>. 2017;24(suppl 1):S57-S74. doi:10.1093/jtm/tax026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/28521004/pubmed" id="28521004" target="_blank">28521004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29145631">
<a name="29145631"></a>Rimmer JE, Harro C, Sack DA, et al. Rifaximin fails to prevent campylobacteriosis in the human challenge model: a randomized, double-blind, placebo-controlled trial. <i>Clin Infect Dis</i>. 2018;66(9):1435-1441. doi:10.1093/cid/cix1014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/29145631/pubmed" id="29145631" target="_blank">29145631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17373916">
<a name="17373916"></a>Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. <i>Aliment Pharmacol Ther</i>. 2007;25(7):781-786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/17373916/pubmed" id="17373916" target="_blank">17373916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23740443">
<a name="23740443"></a>Scarpellini E, Giorgio V, Gabrielli M, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome: a preliminary study. <i>European Review for Medical and Pharmacological Sciences</i>. 2013;17:1314-1320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/23740443/pubmed" id="23740443" target="_blank">23740443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shen.2020">
<a name="Shen.2020"></a>Shen B. Management of acute and chronic pouchitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 2, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25562268">
<a name="25562268"></a>Steffen R, Hill DR, DuPont HL. Traveler's diarrhea: a clinical review. <i>JAMA</i>. 2015;313(1):71-80. doi: 10.1001/jama.2014.17006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/25562268/pubmed" id="25562268" target="_blank">25562268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pimentel.2019">
<a name="Pimentel.2019"></a>Talley NJ. Small intestinal bacterial overgrowth: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16760520">
<a name="16760520"></a>Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. <i>Am J Trop Med Hyg</i>. 2006;74(6):1060-1066.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/16760520/pubmed" id="16760520" target="_blank">16760520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25042402">
<a name="25042402"></a>Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. <i>Hepatology</i>. 2014;60(2):715-735.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/25042402/pubmed" id="25042402" target="_blank">25042402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wald.1">
<a name="Wald.1"></a>Wald A. Treatment of irritable bowel syndrome in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 10, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xifaxan.1">
<a name="Xifaxan.1"></a>Xifaxan (rifaximin) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xifaxan.2">
<a name="Xifaxan.2"></a>Xifaxan (rifaximin) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xifaxan.2">
<a name="Xifaxan.2"></a>Xifaxan (rifaximin) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zaxine.1">
<a name="Zaxine.1"></a>Zaxine (rifaximin) [product monograph]. Montreal, Canada: Lupin Pharma Canada Ltd; February 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22966484">
<a name="22966484"></a>Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O. Rifaximin therapy and hepatic encephalopathy: pros and cons. <i>World J Gastrointest Pharmacol Ther</i>. 2012;3(4):62-67. doi:10.4292/wjgpt.v3.i4.62<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/22966484/pubmed" id="22966484" target="_blank">22966484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23507769">
<a name="23507769"></a>Zullo A, Ridola L, Hassan C. Rifaximin therapy and <i>Clostridium difficile</i> infection: a note of caution. <i>J Clin Gastroenterol</i>. 2013;47(8):737. doi:10.1097/MCG.0b013e31828bea4b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/23507769/pubmed" id="23507769" target="_blank">23507769</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10202 Version 274.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
